Astellas Pharma Inc.
Financial Summary for the Six Months Ended March 2027 (IFRS) (Consolidated)
Revenue was approximately 1,270,861 million yen, up 23.4% year-over-year. Core operating income was approximately 424,928 million yen, and core interim profit was approximately 331,499 million yen, both showing substantial increases. Full-year guidance was revised upward on a core basis to 2,330,000 million yen for revenue, core operating income of 700,000 million yen, and core net income of 520,000 million yen. No dividend revision was made; the dividend forecast for the fiscal year is maintained. Foreign exchange had a positive impact.
Key Figures
- Revenue: 1,270,861 million yen (Up 23.4% year-over-year)
- Core Operating Income: 424,928 million yen (Up 50.3% year-over-year)
- Core Interim Profit: 331,499 million yen (Up 56.8% year-over-year)
AI要約
Business Performance Overview
Consolidated revenue for the interim period was 1,270,861 million yen, up 23.4% year-over-year. On a core basis, core operating income was 424,928 million yen and core interim profit was 331,499 million yen, achieving substantial year-over-year increases in both revenue and profit. Growth was driven by expanded sales of key product groups (PADCEV, IZERVAY, VYLOY, VEOZAH, XOSPATA) and favorable foreign exchange effects. The full-year forecast on a core basis has been revised upward to 2,330,000 million yen for revenue, 700,000 million yen for core operating income, and 520,000 million yen for core net income.
Outlook and Capital Allocation
Supplementary materials and an earnings presentation are prepared to explain future performance outlooks. Recent foreign exchange effects have been a positive factor, and continued global expansion and cost management are expected to support results. There was no change to the dividend forecast, and the full-year dividend policy is disclosed based on the financial summary.
Astellas Pharma Inc.
Company overview · Stock price · Financial data · All IR
